Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Taxes (2018 - 2022)

Regenxbio (RGNX) has 5 years of Current Taxes data on record, last reported at $12.7 million in Q1 2022.

  • For Q1 2022, Current Taxes rose 216.4% year-over-year to $12.7 million; the TTM value through Mar 2022 reached $12.7 million, up 216.4%, while the annual FY2021 figure was $11.3 million, 261.24% up from the prior year.
  • Current Taxes reached $12.7 million in Q1 2022 per RGNX's latest filing, up from $11.3 million in the prior quarter.
  • Across five years, Current Taxes topped out at $12.7 million in Q1 2022 and bottomed at $508000.0 in Q3 2019.
  • Average Current Taxes over 5 years is $3.8 million, with a median of $1.8 million recorded in 2018.
  • Peak YoY movement for Current Taxes: plummeted 76.88% in 2019, then soared 261.24% in 2021.
  • A 5-year view of Current Taxes shows it stood at $726000.0 in 2018, then crashed by 30.03% to $508000.0 in 2019, then skyrocketed by 517.13% to $3.1 million in 2020, then skyrocketed by 261.24% to $11.3 million in 2021, then grew by 11.89% to $12.7 million in 2022.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $12.7 million in Q1 2022, $11.3 million in Q4 2021, and $4.0 million in Q1 2021.